TPO and autoimmune thrombocytopenic purpura: Subgroup analysis based on different patient populations indicated that the incidence of any or severe bleeding events did not significantly decrease with TPO-RAs vs. placebo in pediatric ITP patients (RR: 0.78, 95% CI: 0.43–1.42; RR: 0.58, 95% CI: 0.03–12.09; respectively Supplementary Fig. S5, Table 3).